BMS-262084 manufacturers
- BMS-262084
-
- $2780.00 / 50mg
-
2026-01-05
- CAS:253174-92-4
- Min. Order:
- Purity:
- Supply Ability: 10g
- BMS-262084
-
- $10.00 / 1G
-
2022-10-15
- CAS:253174-92-4
- Min. Order: 100G
- Purity: 99.99%
- Supply Ability: 20MT
- BMS-262084
-
- $15.00 / 1KG
-
2021-07-02
- CAS:253174-92-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | BMS-262084 Basic information |
| Product Name: | BMS-262084 | | Synonyms: | BMS-262084;CHEMBL71037;I0IR71971G;UNII-I0IR71971G;(2S,3R)-1-[4-(tert-butylcarbamoyl)piperazine-1-carbonyl]-3-[3-(diaminomethylideneamino)propyl]-4-oxoazetidine-2-carboxylicacid;2-Azetidinecarboxylic acid, 3-[3-[(aminoiminomethyl)amino]propyl]-1-[[4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperazinyl]carbonyl]-4-oxo-, (2S,3R)- | | CAS: | 253174-92-4 | | MF: | C18H31N7O5 | | MW: | 425.48 | | EINECS: | | | Product Categories: | | | Mol File: | 253174-92-4.mol |  |
| | BMS-262084 Chemical Properties |
| density | 1.46±0.1 g/cm3(Predicted) | | form | Solid | | pka | 2.96±0.40(Predicted) | | color | White to off-white |
| | BMS-262084 Usage And Synthesis |
| Uses | BMS-262084 is a potent, selective and irreversible inhibitor of factor XIa, with an IC50 of 2.8 nM against human factor XIa. BMS-262084 also inhibits human tryptase (IC50=5 nM). BMS-262084 exhibits antithrombotic effects[1][2]. | | in vivo | BMS-262084 (2-12 mg/kg + 2-12 mg/kg/h; i.v.) reduces carotid artery thrombus weight and improves both vessel patency and integrated flow in rats[1].
| Animal Model: | Male Sprague Dawley rats (310-390 g) were induced venous thrombosis by FeCl2[1] | | Dosage: | 2 mg/kg + 2 mg/kg/h, 6 mg/kg + 6 mg/kg/h, 12 mg/kg + 12 mg/kg/h | | Administration: | I.v. 10 min before FeCl2 application | | Result: | Reduced carotid artery thrombus weight by 73% at the dose of 12 mg/kg + 12 mg/kg/h.
Improved both vessel patency and integrated flow. |
| | References | [1] Schumacher WA, et, al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol. 2007 Sep 10;570(1-3):167-74. DOI:10.1016/j.ejphar.2007.05.043
[2] Qian X, et, al. A stereoselective synthesis of BMS-262084, an azetidinone-based tryptase inhibitor. J Org Chem. 2002 May 31;67(11):3595-600. DOI:10.1021/jo010757o |
| | BMS-262084 Preparation Products And Raw materials |
|